Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia

被引：33

作者：

Govind Babu K. ^{[1
]}

Attili V.S.S. ^{[1
]}

Bapsy P.P. ^{[1
]}

Anupama G. ^{[1
]}

机构：

[1] Department of Medical Oncology, Kidwai Memorial Institute of Oncology

来源：

International Ophthalmology | 2007年 / 27卷 / 1期

关键词：

Chronic myeloid leukemia; Imatinib; Opticneuritis;

D O I：

10.1007/s10792-007-9038-9

中图分类号：

学科分类号：

摘要：

Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug. © Springer Science+Business Media, Inc. 2007.

引用

页码：43 / 44

页数：1

共 3 条

[1]

O'Brien S.G., Guilhot F., Larson R.A., Et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 348, 11, pp. 994-1004, (2003)

[2]

Kantarjian H., Talpaz M., O'Brien S., Et al., High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, Blood, 103, 8, pp. 2873-2878, (2004)

[3]

Fraunfelder F.W., Solomon J., Druker B.J., Esmaeli B., Kuyl J., Ocular side-effects associated with imatinib mesylate, J Ocul Pharmacol Ther, 19, 4, pp. 371-375, (2003)

← 1 →